Anzeige
Erschienen in:
29.07.2023 | Adis Summary of Research
Adis Summary of Research: Safety, Effectiveness, and Immunogenicity 6 Months After BNT162B2 mRNA Vaccine in Frail Nursing Home Residents
Erschienen in: Drugs & Therapy Perspectives | Ausgabe 9/2023
Einloggen, um Zugang zu erhaltenAbstract
Coronavirus disease 2019 (COVID-19) has a high mortality rate among the elderly, particularly among frailer and older individuals living in long-term care facilities (LTCFs). In Spain, a large number of patients in this priority group had received the COVID-19 vaccine, including the mRNA vaccine BNT162B2, by April 2021. This Adis Summary of Research summarizes the effects of the BNT162B2 mRNA vaccine among residents in an LTCF in Spain, based on an observational study. Vaccination in elderly LTCF residents was not linked with an increased safety risk, with no apparent contraindications even in more frail individuals.